IL293753A - Biopharmaceutical preparations and related methods - Google Patents

Biopharmaceutical preparations and related methods

Info

Publication number
IL293753A
IL293753A IL293753A IL29375322A IL293753A IL 293753 A IL293753 A IL 293753A IL 293753 A IL293753 A IL 293753A IL 29375322 A IL29375322 A IL 29375322A IL 293753 A IL293753 A IL 293753A
Authority
IL
Israel
Prior art keywords
seq
variant
composition
heavy chain
antibody
Prior art date
Application number
IL293753A
Other languages
English (en)
Hebrew (he)
Original Assignee
Tesaro Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tesaro Inc filed Critical Tesaro Inc
Publication of IL293753A publication Critical patent/IL293753A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
IL293753A 2019-12-18 2020-12-10 Biopharmaceutical preparations and related methods IL293753A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962949696P 2019-12-18 2019-12-18
US201962950595P 2019-12-19 2019-12-19
PCT/US2020/064241 WO2021126657A1 (en) 2019-12-18 2020-12-10 Biopharmaceutical compositions and related methods

Publications (1)

Publication Number Publication Date
IL293753A true IL293753A (en) 2022-08-01

Family

ID=74125707

Family Applications (1)

Application Number Title Priority Date Filing Date
IL293753A IL293753A (en) 2019-12-18 2020-12-10 Biopharmaceutical preparations and related methods

Country Status (11)

Country Link
US (1) US20230059341A1 (cg-RX-API-DMAC10.html)
EP (1) EP4077388A1 (cg-RX-API-DMAC10.html)
JP (2) JP2023507981A (cg-RX-API-DMAC10.html)
KR (1) KR20220129548A (cg-RX-API-DMAC10.html)
CN (1) CN115298218A (cg-RX-API-DMAC10.html)
AU (2) AU2020407007A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022014694A2 (cg-RX-API-DMAC10.html)
CA (1) CA3164600A1 (cg-RX-API-DMAC10.html)
IL (1) IL293753A (cg-RX-API-DMAC10.html)
MX (1) MX2022007464A (cg-RX-API-DMAC10.html)
WO (1) WO2021126657A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230355757A1 (en) * 2019-12-20 2023-11-09 Formycon Ag Formulations of anti-pd1 antibodies
EP4626927A1 (en) * 2022-11-30 2025-10-08 Tesaro, Inc. Methods of treating cancer with anti-pd-1-antibodies
EP4763222A1 (en) * 2025-08-25 2026-06-24 Qilu Pharmaceutical Co., Ltd. A composition comprising apitegromab

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015017307A2 (pt) * 2013-03-14 2017-11-21 Abbvie Inc composições de espécies com baixa acidez e métodos para produção e uso das mesmas
RS61400B1 (sr) 2013-05-02 2021-02-26 Anaptysbio Inc Antitela usmerena protiv programirane smrti-1 (pd-1)
MA41463A (fr) 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
PL3277321T3 (pl) 2015-04-01 2024-11-18 Anaptysbio, Inc. Przeciwciała skierowane przeciwko białku 3 immunoglobuliny limfocytów t i mucyny (tim-3)
ES3053874T3 (en) * 2015-08-24 2026-01-27 Glaxosmithkline Ip No 2 Ltd Biopharmaceutical compositions
EP3357508A4 (en) * 2015-09-28 2019-04-24 Suzhou Suncadia Biopharmaceuticals Co., Ltd. STABLE PHARMACEUTICAL ANTI-PD-1 ANTIBODY PREPARATION AND APPLICATION THEREOF IN MEDICINE
DK3386541T3 (da) * 2015-12-07 2020-09-28 Merck Patent Gmbh Vandig farmaceutisk formulering omfattende anti-pd-1-antistof avelumab
CN110049777A (zh) * 2016-11-01 2019-07-23 安奈普泰斯生物有限公司 针对程序性死亡-1(pd-1)的抗体
PT3565844T (pt) 2017-01-09 2023-05-02 Tesaro Inc Métodos de tratamento de cancro com anticorpos anti-pd-1
JOP20190260A1 (ar) * 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها

Also Published As

Publication number Publication date
KR20220129548A (ko) 2022-09-23
CA3164600A1 (en) 2021-06-24
AU2020407007A1 (en) 2022-06-23
JP2026027328A (ja) 2026-02-18
EP4077388A1 (en) 2022-10-26
CN115298218A (zh) 2022-11-04
WO2021126657A1 (en) 2021-06-24
JP2023507981A (ja) 2023-02-28
MX2022007464A (es) 2022-06-27
AU2025203823A1 (en) 2025-06-19
US20230059341A1 (en) 2023-02-23
BR112022014694A2 (pt) 2022-09-06

Similar Documents

Publication Publication Date Title
IL293244A (en) Agonist antibodies against icos and their uses
CN115969970A (zh) Abcg2抑制剂与sacituzumab govitecan的组合
US20150259419A1 (en) Anti-MCAM Antibodies and Associated Methods of Use
KR20180067693A (ko) 항-cd38 항체의 피하 제제 및 이의 용도
JP2020504141A (ja) 抗pd−1抗体を用いてがんを処置する方法
AU2025203823A1 (en) Biopharmaceutical compositions and related methods
AU2020304112A1 (en) Formulations containing anti-CD47/PD-L1 bispecific antibody and preparation method therefor and use thereof
CN110546163A (zh) 抗-tigit抗原结合蛋白及其使用方法
BR112021006784A2 (pt) Construtos de anticorpo que se ligam a 4-1bb e antígenos associados a tumor e usos dos mesmos
WO2017208210A1 (en) Anti-mcam antibodies and associated methods of use
KR20250153216A (ko) Fap/cd40 결합 분자의 약학적 조성물 및 이의 의약적 용도
TW202421661A (zh) Igf1r抗體
TW202233671A (zh) Peg結合抗mertk抗體及其使用方法
TW202330027A (zh) 抗cd-47抗體製劑
US20250340643A1 (en) Anti-CTLA Antibody Compositions and Related Methods
BR122024025522A2 (pt) Composições biofarmacêuticas, formulação, dispositivo de injeção, meio de cultura celular e eluato que compreendem as ditas composições e usos terapêuticos das mesmas
HK40083648A (zh) 生物藥物組合物和相關方法
WO2023185732A1 (zh) 包含抗Claudin18.2和CD3双特异性抗体的制剂及其制备方法和用途
CN118946583A (zh) 用t细胞接合分子治疗前列腺癌的联合治疗方法
EP4638506A1 (en) Combination therapies for the treatment of cancer
HK40018067A (en) Anti-tigit antigen-binding proteins and methods of use thereof